SEROLOGICAL OUTCOMES OF TREATMENT WITH 3D-CRT AND IMRT IN LOCALIZED PROSTATE CANCER
Keywords:
Key words: 3D-CRT (3-dimensional Conformal Radiotherapy), IMRT (Intensity-modulated radiation therapy), PSA, Prostate cancer, OutcomeAbstract
Background: Prostate cancer ranks the second most frequent cancer encountered worldwide in men. Radiotherapy has been effectively used to treat localized prostate cancer. Over the years more effective radiation techniques like 3D-Conformal Radiation Therapy (3D-CRT), Proton Therapy, Intensity Modulated Radiation Therapy (IMRT), and Brachytherapy has been evolved and effectively used to deliver radiation therapy. Herein, we compare serological outcomes of two radiation treatment techniques intensity modulated radiation therapy (IMRT) and 3- dimensional conformal radiation therapy (3DCRT) in localized prostate adenocarcinoma. Methods: It is a cohort study conducted at Department of Oncology, Dr Ziauddin Hospital, Karachi. Patients with localized prostate adenocarcinoma meeting the inclusion criteria were recruited from July 2016 to June 2022, underwent treatment with a total dose >74 Gy using two different advanced radiotherapy techniques, i.e., IMRT and 3D-CRT. Serum PSA levels were assessed prior to treatment, and 6 weeks and 12 months after treatment. Paired t-Test was applied to identify the difference in PSA levels before, and after the treatment. p-value less than 0.05 was taken as significant at 95% confidence interval. Results: A total of 78 patients with 39 in each group. The mean age of patients in 3D-CRT group was 68±10 years while in IMRT group was 68±07 years. Six weeks after initiation of treatment, we observed that both the treatment methods, i.e., 3D-CRT and IMRT reduced the PSA levels significantly p-value = 0.001 respectively. There was no significant difference in the mean of PSA levels on 06th week and 12th months. Furthermore, the analysis of PSA levels at 12th months when compared with the baseline PSA levels came highly significant in both the groups as depicted in paired-t teat analysis of PSA levels with acceptable toxicity. Conclusion: Radiation therapy modalities 3D-CRT and IMRT both showed a significant serological response with minimal or acceptable gastrointestinal and genitourinary toxicities in the 3D-CRT group in comparison to the IMRT group. Although the sample size is relatively smaller, but the results of this study are encouraging to treat those patients on 3D-CRT, who cannot afford more expansive radiotherapy treatment technique like IMRT.References
Janjua TK, Yousuf MA, Iqbal MT, Memon SM, Abdullah A, Faridi N, et al. Incidental finding of prostate cancer in transurethral resection of prostate (TURP) specimens: a retrospective analysis from a tertiary care hospital in Pakistan. Pan Afr Med J 2021;39(1):20.
Perdana NR, Mochtar CA, Umbas R, Hamid ARA. The risk factors of prostate cancer and its prevention: a literature review. Acta Med Indones 2017;48(3):228–38.
Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol 2018;25(6):524–31.
Tian JY, Guo FJ, Zheng GY, Ahmad AJC. Prostate cancer: updates on current strategies for screening, diagnosis and clinical implications of treatment modalities. Carcinogenesis 2018;39(3):307–17.
Moris L, Cumberbatch MG, Van den Broeck T, Gandaglia G, Fossati N, Kelly B, et al. Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review. Eur Urol 2020;77(5):614–27.
Nguyen D, Long T, Jia X, Lu W, Gu X, Iqbal Z, et al. A feasibility study for predicting optimal radiation therapy dose distributions of prostate cancer patients from patient anatomy using deep learning. Sci Rep 2019;9(1):1076.
Potters L, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2008;179(5 Suppl):S20–4.
Fossati N, Willemse PM, van den Bergh RC, van den Bergh RCN, Yuan CY, Briers E, et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur Urol 2017;7291):84–109.
Pan HY, Jiang J, Hoffman KE, Tang C, Choi SL, Nguyen QN, et al. Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer. J Clin Oncol 2018;36(18):1823–30.
Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer. Eur Urol 2021;80(3):280–92.
Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65(4):965–74.
Hanif S, Osmani AH, Mallick J. Treatment Related Acute Toxicities Between Treatment with 3D-CRT and IMRT in Localised Prostate Cancer. J Coll Physicians Surg Pak 2024;34(5):573–7.
Akhtar S, Hassan F, Ahmad S, El-Affendi MA, Khan MI. The prevalence of prostate cancer in Pakistan: A systematic review and meta-analysis. Heliyon 2023;9(10):e20350.
Siri FH, Salehiniya H. Prostate cancer in Iran: an epidemiological review. J Gastrointest Cancer 2020;51:418–24.
Bosland MC, Nettey OS, Phillips AA, Anunobi CC, Akinloye O, Ekanem IA, et al. Prevalence of prostate cancer at autopsy in Nigeria—a preliminary report. Prostate 2021;81(9):553–9.
Viani G, Hamamura AC, Faustino AC. Intensity modulated radiotherapy (IMRT) or conformational radiotherapy (3D-CRT) with conventional fractionation for prostate cancer: Is there any clinical difference? Int Braz J Urol 2019;45(6):1105–12.
Fischer-Valuck BW, Rao YJ, Michalski JM. Intensity-modulated radiotherapy for prostate cancer. Transl Androl Urol 2018;7(3):297.
Konski AJTa, urology. Cost effectiveness of prostate cancer radiotherapy. Transl Androl Urol 2018;7(3):371–7.
Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol 2018;29(2):377–85.
Malik SS, Batool R, Masood N, Yasmin A. Risk factors for prostate cancer: A multifactorial case-control study. Curr Probl Cancer 2018;42(3):337–43.
Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EA, Hunter‐Merrill RA, Mariotto AB, et al. Is prostate cancer different in black men? Answers from 3 natural history models. Cancer 2017;123(12):2312–19.
Arthur R, Williams R, Garmo H, Holmberg L, Stattin P, Malmström H, et al. Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study. Int J Cancer 2018;142(11):2254–62.
Fukuokaya W, Kim S, Natsuyama T, Matsuzaki K, Shiomi H, Kitoh H, et al. Significance of prostate-specific antigen kinetics after three-dimensional conformal radiotherapy with androgen deprivation therapy in patients with localized prostate cancer. Int J Clin Oncol 2018;23(2):361–7.
Parikh RR, Byun J, Goyal S, Kim IY. Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer. Prostate 2017;77(6):559–72.
Inaba K, Tsuchida K, Kashihara T, Umezawa R, Takahashi K, Okuma K, et al. Treatment results of radiotherapy to both the prostate and metastatic sites in patients with bone metastatic prostate cancer. J Radiat Res 2021;62(3):511–6.
Takano S, Shibamoto Y, Takemoto S, Sugie C, Manabe Y, Yanagi T, et al. PSA Levels after IMRT for Prostate Cancer: Discriminating Second Plateau from PSA Failure. Int J Radiat Oncol Biol Phys 2020;108(3):e890.
Dutz A, Baumann M, Krause M. Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer. Acta Oncol 2019;58(6):916–25.
Carrier F, Liao Y, Mendenhall N, Guerrieri P, Todor D, Ahmad A, et al. Three Discipline Collaborative Radiation Therapy (3DCRT) Special Debate: I would treat prostate cancer with proton therapy. J Appl Clin Med Phys 2019;20(7):7–14.
Barber L, Gerke T, Markt SC, Peisch SF, Wilson KM, Ahearn T, et al. Family history of breast or prostate cancer and prostate cancer risk. Clin Cancer Res 2018;24(23):5910–7.
Akhtar S, Ali A, Ahmad S, Khan MI, Shah S, Hassan F. The prevalence of foot ulcers in diabetic patients in Pakistan: a systematic review and meta-analysis. Front Public Health 2022;10:1017201.
Akhtar S, Ramzan M, Shah S, Ahmad I, Khan MI, Ahmad S, et al. Forecasting exchange rate of Pakistan using time series analysis. Math Probl Eng 2022;2022(1):9108580.
Published
Issue
Section
License
Copyright (c) 2024 Shoaib Hanif, Asif Husain Osmani, Jawaid Malick, Jawaid Malick
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
